Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Positive Outlook for Arcturus Therapeutics' Vaccine Production and Distribution Spurs Buy Rating
Unveiling 3 Analyst Insights On Arcturus Therapeutics
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $58
Express News | Self-Amplifying Mrna Covid-19 Vaccine Demonstrates Superior Immune Response Compared With Mrna Vaccine at 12 Months Post-Vaccination
Arcturus Therapeutics, CSL's Updated Covid-19 Vaccine Approved in Japan
Express News | Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-Amplifying Mrna Covid-19 Vaccine for Protection Against Jn.1 Strain, to Be Distributed in Japan by Meiji Seika Pharma
Leerink Partners Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
Leerink Partners analyst Lili (Aurélie) Nsongo maintains $Arcturus Therapeutics(ARCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 0.0% and a total average
Arcturus Therapeutics: Strong Buy Rating on Promising Vaccine Distribution and Advancements in Rare Disease Treatments
Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeutics
While Shareholders of Arcturus Therapeutics Holdings (NASDAQ:ARCT) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate
Arcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According to Short Sellers
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
William Blair analyst Myles Minter maintains $Arcturus Therapeutics(ARCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 47.5% and a total average return of 8.5%
Buy Rating Affirmed: Arcturus Therapeutics' Promising Cystic Fibrosis Program Progress
Express News | Arcturus Therapeutics : To Initiate Phase 2 Study for Arct-032
Express News | Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for Arct-032, an Investigational Inhaled Mrna Therapeutic to Treat Cystic Fibrosis
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled MRNA Therapeutic to Treat Cystic Fibrosis
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences